Mirvie Granted Breakthrough Device Designation For Test To Identify Risk Of Preeclampsia
Mirvie’s RNA platform can identify 75% of women who develop preeclampsia months before symptoms occur.
You may also be interested in...
This year’s annual HLTH meeting drew more than 9,000 people to Las Vegas from 13-16 November and hundreds of exhibitors. In this first part of a two-part roundup, Medtech Insight highlights interviews with C-suite executives at Mirvie, Grail, Biofourmis, Komodo Health and Babson Diagnostics.
Minute Insight: Abbott Wins Expanded FDA Approval For Proclaim XR Spinal Cord Stimulator For Diabetic Peripheral Neuropathy
Abbott said a major competitive benefit of the Proclaim XR SCS system is the battery life of up to 10 years at low settings.
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb provides highlights from the recent CES 2023 conference in Las Vegas. Reed Miller discusses Abbott’s VR partnership with the Blood Centers for America and Barnaby Pickering highlights Bayer’s jump into medtech with its buyout of Blackford Analysis.